Last updated: 18 September 2020 at 5:01pm EST

Nadav Navon Net Worth



Nadav Navon biography

Dr. Nadav Navon has been appointed Chief Operating Officer at Intec Pharma Ltd effective July 27, 2017. His work experience includes the following roles: Executive Vice President-Research & Development and Operations at the Company (from March 31, 2015), Vice President of Research & Development and Operations at the Company (from May 2013), Head of analytical and quality assurance operations at Sharon Laboratories Ltd (2001-2006) and Leader of a number of research and development projects at the Negev’s Nuclear Research Center. Dr. Navon holds a Bachelor of Science degree in Chemistry, a Doctorate of Science degree in Inorganic and Analytical Chemistry and a MBA degree, all from Ben Gurion University.



How old is Nadav Navon?

Nadav Navon is 48, he's been the Chief Operating Officer of Intec Parent Inc since 2017. There are 6 older and 1 younger executives at Intec Parent Inc. The oldest executive at Intec Parent Inc is John Kozarich, 70, who is the Chairman of the Board.

What's Nadav Navon's mailing address?

Nadav's mailing address filed with the SEC is C/O INTEC PHARMA LTD., 12 HARTOM STREET, JERUSALEM, L3, 9777512.

Insiders trading at Intec Parent Inc

Over the last 6 years, insiders at Intec Parent Inc have traded over $284,445 worth of Intec Parent Inc stock and bought 245,000 units worth $117,350 . The most active insiders traders include Pharma Technologies Ltd.Ore..., Roger Pomerantz oraz Jeffrey A Meckler. On average, Intec Parent Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,864,936. The most recent stock trade was executed by Pharma Technologies Ltd.Ore... on 31 January 2020, trading 915,951 units of NTEC stock currently worth $283,945.



What does Intec Parent Inc do?

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.



Intec Parent Inc executives and stock owners

Intec Parent Inc executives and other stock owners filed with the SEC include: